MetLife's core underwriting remains resilient, with combined ratios consistently between 89.1% and 95.3% over the past ten quarters, and Q2 2026 operating cash flow covering net income by 3.03x.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has been erratic, with a 9.9% year-over-year increase in Q2 2026 but a 7.7% decline in Q3 2025, while the combined ratio remained stable at 94.5% in Q2 2026, indicating consistent underwriting profitability.
MetLife’s five‑segment structure—insurance, annuities, employee benefits, asset management, and group benefits—provides earnings stability and diversification. The company’s scale and wide product mix help it weather market volatility.
VII is expected to rebound from 25% of normal in 2023 to 75% in 2024, adding roughly $300‑$325 million to earnings. This recovery boosts profitability and supports future growth.
Voluntary benefits in the Group Benefits segment are expanding, and retirement spreads are improving, underscoring MetLife’s strong market positioning. The Asia segment contributes about 25% of earnings, with leading positions in Mexico and Chile.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $2.78+0.4% vs $2.77 | $20.5B+3.4% vs $19.9B |
Q3 2026 Aug 5, 2026 | $2.43+5.7% vs $2.30 | $19.1B-3.0% vs $19.7B |
Q2 2026 May 6, 2026 | $2.42+6.6% vs $2.27 | $19.7B+1.0% vs $19.5B |
Q1 2026 Feb 4, 2026 | $2.58+10.3% vs $2.34 | $23.8B-12.5% vs $27.2B |
The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier Global and Builders FirstSource.
MetLife, Inc. (NYSE: MET - Get Free Report)'s stock price reached a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $104.00 and last traded at $105.7040, with a volume of 2,037 shares. The stock had previously closed at $102.89. The financial services
MetLife, Inc. ( MET ) Q3 2026 Earnings Call November 5, 2026 9:00 AM EST Company Participants John Hall - Senior VP, Head of Investor Relations & Executive VP and Treasurer Michel Khalaf - CEO, President & Director John McCallion - Executive VP, CFO & Head of Investment Management Ramy Tadros - Regional President of U.S. Business & Head of MetLife Holdings Conference Call Participants Ryan Krueger - Keefe, Bruyette, & Woods, Inc., Research Division Suneet Kamath - Jefferies LLC, Research Division Thomas Gallagher - Evercore ISI Institutional Equities, Research Division Wesley Carmichael - Wells Fargo Securities, LLC, Research Division Taylor Scott - Barclays Bank PLC, Research Division Wilma Jackson Burdis - Raymond James & Associates, Inc., Research Division Francis Matten - BMO Capital Markets Equity Research Pablo Singzon - JPMorgan Chase & Co, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to the MetLife Third Quarter 2026 Earnings Conference Call.
MetLife's Q3 2026 earnings beat estimates on higher investment income and business growth, while rising expenses and actuarial adjustments temper gains.
Benchmark MET against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for MetLife, Inc. (MET)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $98.27 | $63.23B | 20.47 | 10.22% | 4.38% | 11.93% | 2.31% | |
| $119.24 | $41.38B | 11.67 | -13.74% | 6.17% | 11.21% | 4.62% | |
| $40.05 | $7.66B | 6.86 | 1.24% | 12.18% | 21.99% | 4.36% | |
| $76.75 | $12.15B | 17.93 | 2.07% | 1.96% | 2.23% | 2.31% | |
| $110.91 | $23.96B | 21.13 | -3.11% | 11.82% | 15.77% | 2.73% | |
| $52.66 | $14.37B | -10.90 | -6.21% | -8.72% | -51.38% | 2% |
MetLife, Inc. (MET) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
MetLife, Inc. (MET) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 29, 2026·SEC
Jun 22, 2026·SEC
Get notified when MET posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MetLife, Inc. (MET) stock FAQ — growth, dividends, profitability & financials explained
MetLife, Inc. (MET) grew revenue by 10.2% in fiscal year 2025, compared with the prior fiscal year.
Yes. MetLife, Inc. (MET) earned $3.63B in net income over the trailing twelve months (a 4.6% net margin).
Yes. MetLife, Inc. (MET) pays a dividend that yields 2.31% at the current price, a moderate yield.
MetLife, Inc. (MET) had a return on equity (ROE) of 11.9% in fiscal year 2025. That is in line with the market's typical 10-15%.
MetLife, Inc. (MET) has a combined ratio of 94.0%. A ratio below 100% indicates underwriting profitability.
